ARQ Wealth Advisors LLC Has $2.05 Million Holdings in Thermo Fisher Scientific Inc. $TMO

ARQ Wealth Advisors LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 461.6% in the 1st quarter, Holdings Channel reports. The institutional investor owned 4,173 shares of the medical research company’s stock after acquiring an additional 3,430 shares during the period. ARQ Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,051,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Diversify Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 59.1% in the 1st quarter. Diversify Wealth Management LLC now owns 1,834 shares of the medical research company’s stock valued at $855,000 after purchasing an additional 681 shares during the last quarter. Pittenger & Anderson Inc. raised its holdings in Thermo Fisher Scientific by 545.2% during the first quarter. Pittenger & Anderson Inc. now owns 7,742 shares of the medical research company’s stock valued at $3,805,000 after buying an additional 6,542 shares in the last quarter. Castle Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 7.8% during the 1st quarter. Castle Wealth Management LLC now owns 2,601 shares of the medical research company’s stock worth $1,280,000 after acquiring an additional 188 shares in the last quarter. Fifth Third Bancorp increased its holdings in shares of Thermo Fisher Scientific by 27.2% during the 1st quarter. Fifth Third Bancorp now owns 418,258 shares of the medical research company’s stock valued at $205,586,000 after acquiring an additional 89,478 shares during the last quarter. Finally, Sovran Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 10.2% in the 1st quarter. Sovran Advisors LLC now owns 452 shares of the medical research company’s stock valued at $217,000 after acquiring an additional 42 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMO has been the topic of several analyst reports. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They set a “market perform” rating and a $520.00 price target on the stock. Barclays lowered their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Piper Sandler started coverage on Thermo Fisher Scientific in a research report on Thursday, June 11th. They set a “neutral” rating and a $510.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $602.14.

Insider Activity at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO traded up $2.01 during midday trading on Friday, hitting $526.72. The company had a trading volume of 1,233,008 shares, compared to its average volume of 1,993,707. The firm has a fifty day simple moving average of $478.23 and a two-hundred day simple moving average of $516.44. Thermo Fisher Scientific Inc. has a fifty-two week low of $403.36 and a fifty-two week high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a market cap of $195.74 billion, a price-to-earnings ratio of 28.96, a P/E/G ratio of 2.33 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the company earned $5.15 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.